Mirabegron in the Management of Overactive Bladder Syndrome

Figures & data

Table 1 Primary Endpoints for Phase III Trials Evaluating Mirabegron in Patients with OAB

Trial		Treatment	Mean Number of Micturitions/24 h (SE)	P value	Mean Number of Incontinence Episodes/24 h (SE)	P value
SCORPIO^Citation40	N =1987 12 week treatment	Mirabegron 50 mg	−1.93 (0.11)	<0.001	−1.57 (0.11)	0.003
		Mirabegron 100 mg	−1.77 (0.10)	0.005	−1.46 (0.11)	0.010
		Tolterodine ER 4 mg	−1.59 (0.11)	0.11	−1.27 (0.11)	0.11
		Placebo	−1.34 (0.11)	–	−1.17 (0.11)	–
ARIES^Citation42	N=1328 12 week treatment	Mirabegron 50 mg	−1.66 (0.13_	<0.05	−1.47 (0.11)	<0.05
		Mirabegron 100 mg	−1.75 (0.14)	<0.05	−1.63 (0.12)	<0.05
		Placebo	−1.05 (0.13)	<0.05	−1.13 (0.11)	<0.05
CAPRICORN^Citation43	N=1306 12 week treatment	Mirabegron 25 mg	−1.65 (0.13)	0.007	−1.36 (0.12)	0.005
		Mirabegron 50 mg	−1.60 (0.12)	0.015	−1.38 (0.12)	0.001
Japanese patient trial^Citation48	N=1139 16 week treatment	Mirabegron 50 mg	−1.67 (2.21)	<0.001	−1.12 (1.48)	<0.05
		Tolterodine ER 4 mg	−1.4 (2.17)	––	−0.97 (1.61)	–
		Placebo	−0.86 (2.35)	–	−0.66 (1.86)	–
TAURUS^Citation49	N=2444 52 week treatment	Mirabegron 50 mg	−1.30	–	−1.05	–
		Mirabegron 100 mg	−1.43	–	−1.23	–
		Tolterodine ER 4 mg	−1.47	–	−1.33	–

Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther. 2012;92(6):696–706. doi:10.1038/clpt.2012.181

 PubMed Web of Science ®Google Scholar

Khullar V, Cambronero J, Angulo JC, et al. Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urol. 2013;13:45. doi:10.1186/1471-2490-13-45

 PubMed Web of Science ®Google Scholar

Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–1395. doi:10.1016/j.juro.2012.10.017

 PubMed Web of Science ®Google Scholar

Kuo HC, Lee KS, Na Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34(7):685–692. doi:10.1002/nau.22645

 PubMed Web of Science ®Google Scholar

Yamaguchi O, Marui E, Kakizaki H, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–960. doi:10.1111/bju.12649

 PubMed Web of Science ®Google Scholar